Skip to main content
  • Immunotherapy
    in Actions
    The new wave of immunotherapy antibodies in cancers and rare haematological diseases
  • ElsaLys Biotech
    A clinical stage immuno-oncology company that designs and develops
    a new generation of therapeutic antibodies

Welcome to ElsaLys Biotech

ELSALYS BIOTECH is a pharmaceutical company which develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases.
Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.

Today ELSALYS BIOTECH is conducting 5 proprietary development programs including LEUKOTAC®, an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease.

The company is acting today in 3 main medical fields :

New Updates

Discover our latest news regarding our pipeline, our partnerships and more

Thu, 03/15/2018 - 17:00
  • A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute gra

Thu, 02/22/2018 - 17:00
  • ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert

Thu, 10/12/2017 - 17:00
  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i


Subcribe to our newsletter